Endocrine Abstracts

Introduction: Somatostatin analogues (SSAs) are the mainstay treatment for carcinoid syndrome. ELECT is a large multinational phase 3 study evaluating rescue therapy use as a measure for control of carcinoid syndrome symptoms with LAN-ATG.Methods: Eligible patients had histologically-confirmed GEP-NETs and history of carcinoid syndrome, and were SSA-naïve or responsive to conventional doses of octreotide LAR (≤30 mg/4 weeks) or short-acting (&...